Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is a leader in the emerging market of genomic sequencing and analytics for cancer immunotherapies, with its ImmunoID NeXT platform and NeXT Personal MRD test offering strong revenue potential. The recent acquisition offer from Tempus AI at a significant premium further validates Personalis' technology and growth potential. While the deal may face some volatility, Personalis' strong financials and growing market share make it a promising investment opportunity.

Bears say

Personalis is likely to face several challenges in the future, such as a lack of profitability, low adoption of its products, and potential competition from other companies in the market. The recent acquisition by Tempus AI at a high multiple also raises concerns about the company's valuation and potential for future growth. Additionally, volatility in budgets and ordering patterns from its pharma partners could impact the company's revenue and impact its ability to achieve profitability.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.